Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition in murine models of breast, colorectal, and prostate cancers
08. November 2024 14:51 ET
|
Io Therapeutics, Inc.
Io Therapeutics, Inc., presents data on IRX5010 showing inhibition of tumor infiltrating T-cells and myeloid derived suppressor cells in multiple cancers
Cancer Immunotherapy Market Research 2024-2032: Personalized Cancer Vaccines and CAR T Cell Therapy Revolutionize Immunotherapy
07. Oktober 2024 07:18 ET
|
Research and Markets
Dublin, Oct. 07, 2024 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Market Report, Forecast by Products, Application, End Users, Countries and Company Analysis, 2024-2032" report has been added to ...
Groundbreaking Market Report Forecasts Significant Growth in Cancer Immunotherapy by 2027
19. September 2024 09:41 ET
|
Research and Markets
Dublin, Sept. 19, 2024 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Markets. The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics by Therapy, by Cancer and by Customer...
ImmunOs Therapeutics AG Raises $11 Million and Further Strengthens Investor Base
17. September 2024 04:00 ET
|
AKAMPION
Existing investors and new investor Double Point Ventures join forces to support ImmunOs TherapeuticsInvestment secures funding of ongoing promising clinical trial of IOS-1002 in solid cancers ...
India Liver Cancer Therapeutics Research Report 2024-2030 Featuring Natco Pharma, Dr. Reddy's Laboratories, Intas Pharmaceuticals, Mylan Pharmaceuticals, Lupin, Biocon, and Hetero Labs
11. September 2024 11:54 ET
|
Research and Markets
Dublin, Sept. 11, 2024 (GLOBE NEWSWIRE) -- The "India Liver Cancer Therapeutics Market, By Region, Competition, Forecast & Opportunities, 2020-2030F" report has been added to ...
ImmunOs Therapeutics Expands Phase I Clinical Trial of IOS-1002 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Solid Tumors
24. Juli 2024 04:00 ET
|
AKAMPION
Dosing of patients in new combination treatment arm – IOS-1002 plus KEYTRUDA Schlieren (Zurich Area), Switzerland – July 24, 2024 – ImmunOs Therapeutics AG, a biopharmaceutical company using its...
Global Cancer Immunotherapy Market Report 2024, with Revenue Forecasts to 2034 for Five Regional and 25 Key National Markets
27. Juni 2024 07:02 ET
|
Research and Markets
Dublin, June 27, 2024 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Market Report 2024-2034" has been added to ResearchAndMarkets.com's offering.World revenue for the Cancer Immunotherapy Market is...
Innovation Waves in Immuno-oncology Therapy Development - Next-gen Cell Therapies and Precision Immunotherapies are Driving Growth and New Product Development
21. März 2024 05:13 ET
|
Research and Markets
Dublin, March 21, 2024 (GLOBE NEWSWIRE) -- The "Innovation Waves in Immuno-oncology Therapy Development" report has been added to ResearchAndMarkets.com's offering. Immuno-oncology (I-O)...
Cancer Immunotherapy Market Research 2024: The Race for the Cures - Forecasts for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer including Executive and Consultant Guides
13. März 2024 11:26 ET
|
Research and Markets
Dublin, March 13, 2024 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Markets. The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics by Therapy, by Cancer and by Customer...
Neuroendocrine Tumor Treatment Market revenue to hit USD 8 Billion by 2035, says Research Nester
12. März 2024 05:00 ET
|
Research Nester
New York, March 12, 2024 (GLOBE NEWSWIRE) -- The global neuroendocrine tumor treatment market size is slated to expand at ~12% CAGR between 2023 and 2035. The market is poised to garner a revenue of...